TrialDiabetes technology & therapeutics2017

Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.

Cynthia Harris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.